CTOs on the Move

Biogen

www.biogen.com

 
We are a biotechnology leader that discovers, develops and delivers innovative therapies to improve the lives of patients with neurodegenerative diseases, hematologic conditions and autoimmune diseases. Patients worldwide benefit every day from our medicines for multiple sclerosis (MS) and hemophilia.
 Founded in 1978, we are one of the world’s oldest independent biotechnology companies. Our development pipeline is focused on areas of high unmet medical need, as we pursue new therapies for patients suffering from diseases with few or no treatment options. These include programs for secondary progressive MS, Alzheimer’s Disease, spinal muscular atrophy, lupus and amyotrophic lateral sclerosis (ALS), amongst others. With ...
  • Number of Employees: >100K
  • Annual Revenue: > $1 Billion
  • www.biogen.com
  • 225 Binney Street
    Cambridge, MA USA 02142
  • Phone: 781.464.2000

Executives

Name Title Contact Details
Richard Nolan
 Deputy Chief Information Security Officer Profile
Dave Clifford
 Head of Technology and AI, BDH Data Profile
Pietr Lindahl
 Deputy Chief Information Security Officer Profile
Keith Sarbaugh
 Vice President, IT Infrastructure, Architecture and Operations Profile
Chris Fahey
 Director of Security Operations Profile

Similar Companies

Dendritic NanoTechnologies

Dendritic NanoTechnologies, Inc. is a Mount Pleasant, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IMIDomics

IMIDomics is a biotechnology company focused on Patient-Centric drug discovery for immune-mediated inflammatory diseases (IMIDs). Our goal is to discover new and impactful IMID drugs by focusing on carefully selected patients, and stratifying populations to identify those most likely to respond. IMIDomics is powered by a unique Clinical Discovery EngineTM, which integrates and analyzes proprietary clinical, epidemiological and patient-derived biomolecular datasets, generated in partnership with the Vall d`Hebron Institute of Research, to establish a deeper understanding of IMID diseases. By doing so, IMIDomics has identified previously unrecognized targets, six of which have been selected for development. By relying on access to well-defined patients and their clinically relevant samples, IMIDomics enhances the probability of successful IMID drug discovery and development for those in need.

Response Genetics

Response Genetics is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cybin

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

BioE

BioE is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.